Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report.
The European Medicines Agency validated the marketing authorization application for Valneva’s Lyme disease vaccine, which it developed with Pfizer
Three dividend stocks near or under $30 caught our attention this August, and at least one of them carries a yield so high it comes with a built-in warning label worth reading before you buy.
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
Millions of dollars are available to eligible Chantix buyers, but consumers have until September 14 to submit a claim.
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac
In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...
Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.
The S&P 500's dividend yield just hit a record low, leaving income investors scrambling for alternatives. Five long-established index members still pay 6% or more, and all carry Buy ratings from top Wall Street analysts.
Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and revenue...
This problem has a solution, and Pfizer is implementing it.
Pfizer agreed to a $44 million Chantix settlement. Here's who may qualify, how to file a claim and the deadline to submit.
Both of these stocks pay more than double the S&P 500 average of 1.1%.
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.